These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25027536)

  • 1. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Aug; 71(15):1288-91. PubMed ID: 25027536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A; Mann HJ
    Am J Health Syst Pharm; 2010 Oct; 67(19):1640-4. PubMed ID: 20852166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.
    Housman ST; Tessier PR; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2011 Dec; 68(23):2265-70. PubMed ID: 22095816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.
    Mann HJ; Demmon SL; Boelk DA; Payne CA; Effron MB; Rajagopalan N; Williams MD; Beck GM; Gopalrathnam G
    Am J Health Syst Pharm; 2004 Dec; 61(24):2664-71. PubMed ID: 15646701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
    Bergquist PA; Manas D; Hunke WA; Reed RA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1218-23. PubMed ID: 11449879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
    Lu J; Liu Q; Kupiec TC; Vail H; Lynch LR; Fam DS; Vu NT
    Int J Pharm Compd; 2021; 25(1):52-61. PubMed ID: 33503010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
    Chan P; Bishop A; Kupiec TC; Trissel LA; Gole D; Jimidar IM; Vermeersch H
    Am J Health Syst Pharm; 2008 Aug; 65(16):1545-51. PubMed ID: 18693210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration.
    Katip W
    Am J Health Syst Pharm; 2017 Jul; 74(14):1099-1102. PubMed ID: 28687555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients.
    Canann D; Tyler LS; Barker B; Condie C
    Am J Health Syst Pharm; 2009 Apr; 66(8):727-9. PubMed ID: 19336832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
    Woloschuk DM; Wermeling JR; Pruemer JM
    Am J Hosp Pharm; 1991 Oct; 48(10):2158-60. PubMed ID: 1781472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility of ciprofloxacin injection with selected drugs and solutions.
    Goodwin SD; Nix DE; Heyd A; Wilton JH
    Am J Hosp Pharm; 1991 Oct; 48(10):2166-71. PubMed ID: 1781473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.
    So W; Kim L; Thabit AK; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2017 Jan; 74(1):e55-e63. PubMed ID: 28007722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
    Cochran BG; Sowinski KM; Fausel C; Overholser BR
    Am J Health Syst Pharm; 2007 Jul; 64(13):1410-4. PubMed ID: 17592007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
    Patel K; Hursting MJ
    Am J Health Syst Pharm; 2005 Jul; 62(13):1381-4. PubMed ID: 15972381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
    Fox LM; Wilder AG; Foushee JA
    Am J Health Syst Pharm; 2013 Mar; 70(6):520-4. PubMed ID: 23456406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
    J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
    Najari Z; Rusho WJ
    Am J Health Syst Pharm; 1997 Jan; 54(2):181-4. PubMed ID: 9117807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
    Hutchings SR; Rusho WJ; Tyler LS
    Am J Health Syst Pharm; 1996 Sep; 53(18):2185-8. PubMed ID: 8879326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.